<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335477</url>
  </required_header>
  <id_info>
    <org_study_id>1199.34</org_study_id>
    <secondary_id>2010-024252-29</secondary_id>
    <nct_id>NCT01335477</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II</brief_title>
  <official_title>A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in
      scarring of the lung and there is a high unmet medical need for effective treatment to halt
      lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the
      death rate.

      In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of
      treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of
      patients treated with high dose of BIBF 1120 compared to placebo.

      Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of
      BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will
      be conducted as a prospective, randomised design with the aim to collect safety and efficacy
      data.

      Respiratory function is globally accepted for assessment of treatment effects in IPF
      patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is
      part of the usual examinations done in IPF patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by &gt;5%, increase by &gt;5%, and change within ≤5%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by &gt;10%, and change within ≤10%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Responders Using 10% Threshold at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of FVC Responders Using 5% Threshold at 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Proportion of SGRQ responders at 52 weeks.
Responders defined as &lt;= -4 points change in change from baseline in SGRQ total score at 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks and 52 weeks</time_frame>
    <description>The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of an Acute IPF Exacerbation Over 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death Over 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to On-treatment Death</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death or Lung Transplant Over 52 Weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC &lt;45% predicted or Carbon monoxide diffusion capacity (DL(CO)) &lt;30% pred or Oxygen saturation on pulse oximetry (SpO2) &lt;88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient receives capsules identical to those containing active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBF 1120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient receives capsules containing BIBF 1120 twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching BIBF 1120 BID</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>BIBF 1120 BID (twice daily)</description>
    <arm_group_label>BIBF 1120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age &gt;= 40 years;

          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European
             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic
             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;

          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if
             available surgical lung biopsy pattern, as assessed by central reviewers, are
             consistent with diagnosis of IPF

          4. Dlco (corrected for Hb): 30%-79% predicted of normal; 5.FVC&gt;= 50% predicted of normal

        Exclusion criteria:

          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) &gt; 1.5 x Upper Limit
             of Normal (ULN)

          2. Bilirubin &gt; 1.5 x ULN;

          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC &lt; 0.7);

          4. Patient likely to have lung transplantation during study (being on transplantation
             list is acceptable for participation);

          5. Myocardial infarction within 6 months;

          6. Unstable angina within 1 month;

          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic
             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event
             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or
             ulcers or major injury or surgery within 3 months);

          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including
             stroke and transient ischemic attacks) within 12 months;

          9. International normalised ratio (INR) &gt; 2, prolongation of prothrombin time (PT) and
             partial thromboplastin time (PTT) by &gt; 50% of institutional ULN);

         10. N-ACetyl Cystein, prednisone &gt; 15mg/day or equivalent received within 2 weeks of visit
             1;

         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of
             visit 1;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.34.10078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.10073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.56001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.86057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin-Buch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coswig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Immenhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maroussi, Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nikaia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.91051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.91053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Banglore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.91056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.91054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.91055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogaki, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka-Sayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tenri, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokushima, Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.81061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yonago, Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.35106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.34.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>November 14, 2014</results_first_submitted>
  <results_first_submitted_qc>January 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2015</results_first_posted>
  <disposition_first_submitted>March 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2014</disposition_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
        </group>
        <group group_id="P2">
          <title>Nintedanib 150 mg Bid</title>
          <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="331"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn, not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than those stated above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): The TS consisted of randomized patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
        </group>
        <group group_id="B2">
          <title>Nintedanib 150 mg Bid</title>
          <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="329"/>
            <count group_id="B3" value="548"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="7.5"/>
                    <measurement group_id="B2" value="66.4" spread="7.9"/>
                    <measurement group_id="B3" value="66.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.</title>
        <description>Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate.</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.</title>
          <description>Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate.</description>
          <population>Treated Set</population>
          <units>mL/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-207.32" spread="19.309"/>
                    <measurement group_id="O2" value="-113.59" spread="15.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Random coefficient regression with fixed effects for treatment, gender, age, height and random effect of patient specific intercept and time.
A hierarchical procedure was used in order to demonstrate the superiority of nintedanib over placebo for one primary and two key secondary endpoints.
The consecutive steps of the hierarchy were only considered if the previous step was significant at the one-sided 2.5% level and the results were in favour of nintedanib.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>The objective of this trial was to assess the superiority of nintedanib 150 mg bid compared to placebo on the annual rate of decline in FVC.</p_value_desc>
            <method>Random coefficient regression</method>
            <method_desc>The Roger-Kenward approximation was used to estimate denominators degrees of freedom.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>93.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>24.907</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>44.78</ci_lower_limit>
            <ci_upper_limit>142.68</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by an Unstructured variance-covariance matrix.
Inter-individual variability is modelled by a Variance-components variance-covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George’s Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks</title>
        <description>This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George’s Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks</title>
          <description>This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="0.891"/>
                    <measurement group_id="O2" value="2.80" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Total score, baseline SGRQ Total score-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0197</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.151</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.95</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio is based on a Cox's regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</title>
        <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</title>
          <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-205.03" spread="16.629"/>
                    <measurement group_id="O2" value="-95.26" spread="14.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>109.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.808</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>70.92</ci_lower_limit>
            <ci_upper_limit>148.62</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</title>
        <description>Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks</title>
          <description>Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.14" spread="0.620"/>
                    <measurement group_id="O2" value="-3.90" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.742</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>5.69</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</title>
        <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</title>
          <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>%predicted</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.15" spread="0.505"/>
                    <measurement group_id="O2" value="-3.09" spread="0.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.607</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>4.25</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</title>
        <description>Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks</title>
          <description>Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.13" spread="0.614"/>
                    <measurement group_id="O2" value="-3.92" spread="0.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.743</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>5.67</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold</title>
        <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by &gt;5%, increase by &gt;5%, and change within ≤5%).</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (for patients with change from baseline in FVC (% predicted) at Week 52)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold</title>
          <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by &gt;5%, increase by &gt;5%, and change within ≤5%).</description>
          <population>Treated Set (for patients with change from baseline in FVC (% predicted) at Week 52)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within ≤ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold</title>
        <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by &gt;10%, and change within ≤10%)</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Treated Set (for patients with change from baseline in FVC (% predicted) at Week 52)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold</title>
          <description>Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by &gt;10%, and change within ≤10%)</description>
          <population>Treated Set (for patients with change from baseline in FVC (% predicted) at Week 52)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within ≤ 10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2"/>
                    <measurement group_id="O2" value="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Responders Using 10% Threshold at 52 Weeks</title>
        <description>FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Responders Using 10% Threshold at 52 Weeks</title>
          <description>FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.93" lower_limit="57.38" upper_limit="70.00"/>
                    <measurement group_id="O2" value="69.60" lower_limit="64.43" upper_limit="74.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1833</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.286</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of FVC Responders Using 5% Threshold at 52 Weeks</title>
        <description>Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of FVC Responders Using 5% Threshold at 52 Weeks</title>
          <description>Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.27" lower_limit="33.04" upper_limit="45.87"/>
                    <measurement group_id="O2" value="53.19" lower_limit="47.79" upper_limit="58.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.794</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)</title>
        <description>Proportion of SGRQ responders at 52 weeks.
Responders defined as &lt;= -4 points change in change from baseline in SGRQ total score at 52 weeks.</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)</title>
          <description>Proportion of SGRQ responders at 52 weeks.
Responders defined as &lt;= -4 points change in change from baseline in SGRQ total score at 52 weeks.</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.89" lower_limit="12.51" upper_limit="22.42"/>
                    <measurement group_id="O2" value="25.23" lower_limit="20.84" upper_limit="30.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression with terms treatment, baseline SGRQ total score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0218</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.664</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
        <description>SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
          <description>SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="1.297"/>
                    <measurement group_id="O2" value="2.03" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Symptoms component, baseline SGRQ Symptoms component-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4019</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.675</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.69</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
        <description>SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
          <description>SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.036"/>
                    <measurement group_id="O2" value="2.85" spread="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ impact component, baseline SGRQ impact component-by-visit and random effect for patient</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0220</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.342</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.71</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
            <estimate_desc>Within-patient error are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
        <description>SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
          <description>SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" spread="1.052"/>
                    <measurement group_id="O2" value="3.89" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Activities component, baseline SGRQ Activities component-by-visit and random effect for patient</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.360</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.97</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
        <description>SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)</title>
          <description>SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.84" spread="0.921"/>
                    <measurement group_id="O2" value="2.72" spread="0.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ-I Total score, baseline SGRQ-I Total score-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.192</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.46</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)</title>
        <description>Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)</title>
          <description>Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" spread="1.300"/>
                    <measurement group_id="O2" value="6.69" spread="1.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SOBQ score, baseline SOBQ score-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1587</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.685</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.68</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</title>
        <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</title>
          <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.325"/>
                    <measurement group_id="O2" value="-0.33" spread="1.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline CASA-Q Cough symptoms score, baseline CASA-Q Cough symptoms score-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2326</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.713</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>5.41</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</title>
        <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)</title>
          <description>The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.39" spread="1.209"/>
                    <measurement group_id="O2" value="-2.58" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline CASA-Q Cough impact score, baseline CASA-Q Cough impact score-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2475</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.564</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>4.88</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patient’s Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)</title>
        <description>Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patient’s Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)</title>
          <description>Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.88" lower_limit="47.27" upper_limit="60.36"/>
                    <measurement group_id="O2" value="61.70" lower_limit="56.34" upper_limit="66.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Logistic regression with term treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0690</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.379</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)</title>
        <description>The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.</description>
        <time_frame>baseline, 12 weeks, 24 weeks and 52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)</title>
          <description>The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.</description>
          <population>Treated Set</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks (N=207, 306)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="15.60"/>
                    <measurement group_id="O2" value="-0.57" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks (N=204, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.86" spread="16.94"/>
                    <measurement group_id="O2" value="-1.10" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (N=178, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.60" spread="17.67"/>
                    <measurement group_id="O2" value="-2.52" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of an Acute IPF Exacerbation Over 52 Weeks</title>
        <description>The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of an Acute IPF Exacerbation Over 52 Weeks</title>
          <description>The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)</description>
          <population>Treated Set</population>
          <units>Participants/Year *100</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The log of the risk ratio was assumed to follow a normal distribution with mean 0 and variance equal to the sum of the reciprocals of the number of patients with at least one exacerbation in each treatment arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Normal distribution</method>
            <method_desc>Risk ratio was calculated as the ratio of risk of exacerbation in both treatment groups.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death Over 52 Weeks</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period).</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death Over 52 Weeks</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period).</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on a Cox´s regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2995</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0"/>
                    <measurement group_id="O2" value="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6654</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to On-treatment Death</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to On-treatment Death</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                    <measurement group_id="O2" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on a Cox´s regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2209</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death or Lung Transplant Over 52 Weeks</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death or Lung Transplant Over 52 Weeks</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1664</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.</title>
        <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC &lt;45% predicted or Carbon monoxide diffusion capacity (DL(CO)) &lt;30% pred or Oxygen saturation on pulse oximetry (SpO2) &lt;88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.</title>
          <description>Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC &lt;45% predicted or Carbon monoxide diffusion capacity (DL(CO)) &lt;30% pred or Oxygen saturation on pulse oximetry (SpO2) &lt;88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).</description>
          <population>Treated Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3"/>
                    <measurement group_id="O2" value="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2123</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Nintedanib 150 mg bid versus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks</title>
        <description>Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks</title>
          <description>Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>percent of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.174"/>
                    <measurement group_id="O2" value="-0.39" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline SpO2, baseline SpO2-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2032</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.213</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks</title>
        <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral administration of Placebo matching nintedanib soft gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 150 mg Bid</title>
            <description>Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks</title>
          <description>Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).</description>
          <population>Treated Set (Only patients with observed cases (OC) values were analysed)</population>
          <units>mmol/min/kPa</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.400" spread="0.0843"/>
                    <measurement group_id="O2" value="-0.286" spread="0.0729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed Model for Repeated Measures with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline DLCO (HGB Corrected) [mmol/min/kPa], baseline DLCO (HGB Corrected) [mmol/min/kPa]-by-visit and random effect for patient.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2600</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1005</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.310</ci_upper_limit>
            <estimate_desc>Within-patient errors are modelled by compound symmetry covariance matrix.
Nintedanib 150 mg bid versus Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first drug administration until 28 days after the last drug administration, up to 425 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral administration of Placebo matching nintedanib soft gelatine capsules.</description>
        </group>
        <group group_id="E2">
          <title>Nintedanib 150mg Bid</title>
          <description>Oral administration of soft gelatine capsules of Nintedanib 150 mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Orbital apex syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Herpes simplex meningoencephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Infective aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pathogen resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Neurofibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Piriformis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Aortic intramural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="308" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

